Vorstand der 3. Universitätsklinik für Innere Medizin

Di, 11/10/2009 - 15:59 – serum

Prim. Univ. Prof. Dr. Richard Greil

Primar Greil

Unsere Klinik ist spezialisiert auf alle Formen von Tumorerkrankungen, gutartigen und bösartigen Veränderungen des blutbildenden Systems, Gerinnungsstörungen, HIV-Infektion und rheumatologischen Erkrankungen. Wir legen großen Wert auf eine patientenorientierte Betreuung. Das heißt, maximale Geschwindigkeit und Effizienz in Beratung und Abklärung basierend auf höchster wissenschaftlicher Qualität.

Wir begleiten die Erkrankten mit all ihren existenziellen, menschlichen, familiären und sozialen Problemen sicher und behütet durch eine ihrer schwierigsten Lebensphasen. Dabei bemühen wir uns um eine multidisziplinäre Zusammenarbeit mit anderen Disziplinen, welches die Voraussetzung für das Gelingen bestmöglicher Versorgung darstellt.

top

Chefsekretariat:

Karin Wetzlinger
Tel.: +43/662/4482-2879
Fax: +43/662/4482-2898

Andrea Stempfer
Tel.: +43/662/4482-4135
Fax: +43/662/4482-2898

Curriculum Vitae Prim. Univ.-Prof. Dr. Richard Greil

27.12.1957	Geboren in Salzburg
1968-1976	Akademisches Gymnasium Salzburg, Matura mit Auszeichnung
1976-1983	Studium der Humanmedizin an der Leopold-Franzens-Universität Innsbruck
1983	Promotion “Sub auspiciis praesidentis rei publicae Austria”
1983	Beginn der Facharztausbildung für Innere Medizin an der Universitätsklinik für Innere Medizin in Innsbruck
1983	Auslandsaufenthalt an der Universität Leiden (Dr. Hans Tanke): Durchflusszytometrie für immunzytologische Techniken
1986	Auslandsaufenthalt am National Cancer Institute, Laboratory of Viral Carcinogenesis, Frederick, USA (Prof.Dr. Ulf Rapp), molekularbiologische Techniken
1988-2002	Gründung, Einrichtung und Leitung des Molekularzytologischen Forschungslabors an der Universitätsklinik für Innere Medizin Innsbruck
1989*	Auslandsaufenthalt am SALK-Institute San Diego (USA) mittels CIBA Foundation Scholarship (Prof. Dr. Inder Verma)
1990	Facharztzuerkennung für Innere Medizin
1991	Auslandsaufenthalt an der London School of Pharmacy, London, UK (Prof. Dr. Gregory Gregoriadis)
1992	Habilitation für das Fach Innere Medizin mit dem Thema “Oncogene expression in normal and neoplastic lymphopoesis”.
1992 – 1996	Leiter der Hämatologischen und Onkologischen Ambulanz der Universitätsklinik für Innere Medizin Innsbruck
1994	Assistenzprofessor mit permanentem Dienstverhältnis
1995	Additivfacharzt (Innere Medizin) für Hämatologie und Onkologie
1997	Ernennung zum a.o. Univ. Professor mit Erlass des Bundesministeriums
1998	Gründungsmitglied des Tiroler Krebsforschungsinstitutes an der Universität Innsbruck
2000-2008	Mitglied der Bioethikkommission des Österreichischen Bundeskanzlers
2001-2004	Wissenschaftlicher Leiter des Tiroler Krebsforschungsinstitutes an der Universität Innsbruck
2004 ff	Vorstand der Universitätsklinik für Innere Medizin III der Landeskrankenanstalten Salzburg, Universitätsklinikum der Paracelsus Medizinischen Privatuniversität und Leiter des Labors für immunologische und molekulare Krebsforschung an der III. Medizinischen Abteilung, Salzburg
2004 ff	Vizepräsident der Austrian Breast and Colorectal Cancer Study Group (ABCSG)
2004 ff	Gründer des Centers for Clinical Cancer and Immunology Trials (CCCIT), einem der größten onkologischen Studienzentren in Österreich
2005	Additivfacharzt (Innere Medizin) für Rheumatologie
2006 ff	Präsident der Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
2007	Additivfacharzt (Innere Medizin) für Infektiologie und Tropenmedizin
2008 ff	Mitglied der Ethikkommission der European Society of Medical Oncology ( ESMO)
2009 ff	Vizepräsident der Österreichischen Akademie für Sexualmedizin (mit dem Schwerpunkt Onkologie)
2009	Gründer und Leiter des Onkologiebeirates des österreichischen Bundesministers für Gesundheit, zur Erstellung eines Österreichischen Krebsplanes
2011-2014	Kuratoriumsmitglied des FWF, Fachreferent Stellvertreter für den Fachbereich Klinische Medizin

Reviewer für	Lancet Oncology, J Exp Medicine, Blood, Leukemia, Acta Haematologica, Heamatologica, European Journal of Hematology, J Immunology, Oncogene, International Journal of Cancer, Annals of Oncology, Oncology, Cancer Letters, Carcinogenesis, Onkologie, Biochemical Pharmacology, Pharmacoeconomics, Transplantation, Quality of Life Research, Gerontology, Wiener Klinische Wochenschrift, Respiration
Grant Reviewer	Europäische Union, Medical Research Council London, Gutachter des Italienischen Ministeriums für Forschungsförderung, Externer Gutachter für Schwerpunktforschungsprogramm der Deutschen Krebshilfe/Mildred Scheel-Stiftung, ständiger Gutachter des Jubiläumsfonds der Österreichischen Nationalbank
Approval reviewer	Österreichischer Experte der „European Medicines Agency“ (EMEA),
Mitgliedschaften	American Association of Cancer Research (AACR) American Society of Hematology (ASH) American Society of Clinical Oncology (ASCO) European Society of Medical Oncology (ESMO) Österreichische und Deutsche Gesellschaft für Hämatologie und Onkologie (ÖGHO, DGHO) European Bone Marrow Transplantation (EBMT)
Publikationen (peer reviewed)	Stand Jan 2013: 330
Impact Factor	Stand Jan 2013: 1643,9
Zitierungen	Stand Feb 2013: 8205
H-Index	Stand Feb 2013: 42
G-Index	Stand Jan 2013: 61
i10-Index	Stand Feb 2013: 155

1. Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A.
Journal of Clinical Oncology.

2. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K.
Blood. 2013 Apr 30. [Epub ahead of print]

3. Azacitidine in patients with WHO-defined AML -- results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R.
Journal of Hematology & Oncology. 2013 Apr 29;6(1):32. [Epub ahead of print]

4. AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab as First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer.
Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
Journal of Clinical Oncology. 2013 Apr 8. [Epub ahead of print]

5. Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M.
British Journal of Cancer. 2013 Mar 19. doi: 10.1038/bjc.2013.114. [Epub ahead of print]

6. ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials.
Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.
Journal of Clinical Oncology. 2013 Mar 18. [Epub ahead of print]

7. A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.
Hufnagl C, Stöcher M, Moik M, Geisberger R, Greil R.
Journal of Nucleic Acids Investigation. 2013. DOI: 10.4081/jnai.2013.e1

8. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K, Weiss L, Kofler B, Melchardt T, Greil R.
Eur J Haematol. 2013 Apr;90(4):349-50. doi: 10.1111/ejh.12065. Epub 2013 Feb 14

9. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; on behalf of the Central European Cooperative Oncology Group.
Lancet Oncology. 2013 Jan 9. [Epub ahead of print]

10. Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt T, Weiss L, Greil R, Egle A.
Leuk Lymphoma. 2013 Jan 3.

11. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R.
Annals of Hematology. 2012 Dec 28.

12. Utility of PCR in the Diagnosis of Invasive Fungal Infections: Real Life Data from a Multi-Centre Study.
Lass-Floerl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, Grander W, Greil R, Russ G, Cerkl P, Eller M, Kropshofer G, Eschertzhuber S, Kathrein H, Schmid S, Beer R, Lorenz I, Theurl I, Nachbaur D.
Journal of Clinical Microbiology. 2012 Dec 26.

13. Topical evening primrose oil for reduction of bortezomib-induced skin reactions.
Auberger J, Vogt S, Hopfinger G, Clausen J, Greil R.
Annals of Hematology. 2012 Dec 22.

14. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN.
British Journal of Haematology. 2012 Dec 4. doi: 10.1111/bjh.12151. [Epub ahead of print]

15. CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
Goetz MP, Suman V, Hoskin TL, Gnant M, Filipits M, Safgren S, Kuffel MJ, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames M, Ingle JN.
Clinical Cancer Research. 2012 Dec 4. [Epub ahead of print]

16. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; on behalf of the ML18147 Study Investigators.
Lancet Oncology. 2012 Nov 15.

17. A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.
Hohla F, Mayer P, Hutter J, Meißnitzer T, Greil R.
Memo - Magazine of European Medical Oncology. Case Report

18. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21 induced motility.
Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, Greil R, Hartmann TN.
Cancer Research. 2012 Nov 1. [Epub ahead of print]

19. What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?
Auberger J, Greil R, Lass-Flörl C.
Expert Review of Anti-Infective Therapy. 2012 Nov;10(11):1229-31.

20. Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma.
Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.
Journal of Clinical Oncology.

21. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Annals of Oncology. 2012 Oct 3. [Epub ahead of print]

22. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Banos A, Köhne CH.
BMC Cancer. 2012 Sep 29;12(1):438. [Epub ahead of print]

23. Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O.
Expert Opinion on Drug Discovery. 2012 Sep 24. [Epub ahead of print]

24. Treating T-cell lymphoma: is there a light at the end of the tunnel?
Hopfinger G, Merkel O, Melchardt T, Greil R.
Memo - Magazine of European Medical Oncology. (2012) 5:174–177 DOI 10.1007/s12254-012-0013-4

25. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue-Lymphoma: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M.
Haematologica-The Hematology Journal. 2012 Sep 14. [Epub ahead of print]

26. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G.
European Journal of Cancer. 2012 Sep 13. pii: S0959-8049(12)00629-6. doi: 10.1016/j.ejca.2012.08.004. [Epub ahead of print]

27. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Reinacher-Schick A, Schulmann K, Modest D, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A.
BMC Cancer. 2012 Aug 9;12(1):349.

28. Safety of immunosuppressants. [Article in German]
Psenak O, Studnicka-Benke A, Greil R.
Zeitschrift fur Rheumatologie. 2012 Jul;71(5):420-9.

29. Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer.
Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R.
Oncologist. 2012 Jun 27. [Epub ahead of print]

30. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D.
Critical Reviews in Oncology/Hematology. 2012 Jun;82(3):370-7. Epub 2011 Sep 7.

31. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, Greil R.
Journal of Molecular Medicine-JMM. 2012 Jun;90(6):681-93. Epub 2011 Dec 29.

32. Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.
ANNALS OF SURGICAL ONCOLOGY. 2012 Jun;19(6):1808-17. Epub 2011 Dec 30.

33. Actinomycin D induces p53-independent cell death and prolongs survival in high risk chronic lymphocytic leukemia.
Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Pinon Hofbauer J, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L and Greil R.
Leukemia. 2012 Jun 1. doi: 10.1038/leu.2012.147. [Epub ahead of print]

34. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C.
Eur J Cancer. 2012 Nov;48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.

35. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, Augustson B, Horvath N, Joshua D, Mollee P, Prince M, Spencer A, Taylor K, Gastl AG, Greil R, Ludwig H, Iskrov I, Uss A, Fillet G, Schots R, van Droogenbroeck J, Maisnar V, Scudla V, Gregersen H, Attal M, Fermand JP, Jaccard A, Macro M, Rossi J-, Dölken G, Engelhardt M, Goldschmidt H, Knop S, Niederwieser D, Crotty G, Nagler A, Rowe J, Shpilberg O, Cafro AM, Caravita T, Foa R, Gobbi M, Zweegman S, Dmoszynska A, Hellmann A, Skotnicki AB, Abdulkadyrov K, Domnikova N, Osmanov E, Rossiev V, Rukavistin O, Alegre A, Capote FJ, Martino ML, Miguel JS, Ahlgren T, Bauer S, Stenner F, Cagirgan S, Schey S, Yong K, Kaplan P, Kyeting E, Lysa T, Maslyak Z, Pylypenko G, Tretyak N.
New England Journal of Medicine. 2012 May 10;366(19):1759-69.

36. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, and Greil R.
Haematologica. 2012 Sep;97(9):1431-1438. Epub 2012 Apr 17

37. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases - a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC, Mohler M, Schon M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vohringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Samonigg H, Seehofer D, Kullmann F, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR.
BMC Cancer. 2012 Apr 11;12(1):144.

38. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie.
Lancet. 2012 Apr 3.

39. Treatment of invasive aspergillosis in cancer patients.
Auberger J, Russ G, Greil R, Egle A.
Memo - Magazine of European Medical Oncology. Volume 4, Number 4, 266-272.

40. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, Sevelda P, Watzke H, Winder G, Greil R, Lang A, Van Belle S, Schrijvers D, Verhoeven D, Demey W, Majois F, Bustin F, Andre C, Espie M, Hacini M, Hardy Bessard AC, Isambert N, Lortholary A, Souquet PJ, Hebbar M, Berretta M, Dazzi C, Ferrarini M, Locatelli M, Lorusso V, Marchetti P, Martoni A, Pastorelli D, Pignata S, Giordano M, Aerts J, Blaisse R, van der Wouw A, Peláez I, Antolin Novoa S, Salgado Pascual JE, Candel VA, Rodríguez-Lescure Á, Palomar L, Soriano Teruel V, Bayne M, McAdam K, Molassiotis A, Rankin E, Samuel L, Chatterjee A, Khan S, Davidson N, Flogegard M, Norberg B, Flygare P, Nordenskjold B.
Annals of Oncology. 2012 Aug;23(8):1986-92. Epub 2012 Mar 6.

41. Primary Immune Thrombocytopenia in Adults - Diagnostics and Treatment Consensus Statement of the Austrian Society of Hematology and Oncology (ÖGHO).
Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A.
Wiener Klinische Wochenschrift. 2012 Mar 3.

42. Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.
Aberger F, Kern D, Greil R, Hartmann TN.
Vitamins & Hormones. 2012;88:25-54.

43. Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity
Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R.
PLoS ONE. 2012. 7(2): e30667.

44. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
Jöhrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN.
Expert Opinion on Biological Therapy. 2012 Feb 15.

45. First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study.
Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C.
Journal of Clinical Oncology. 2012 Feb 13.

46. Supportive Therapie bei Tumorpatienten.
Hohla F, Faber V, Greil R.
Med.ium. 2/3 2012, p. 28-33.

47. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group.
Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.
Journal of Clinical Oncology. 2012 Jan 23.

48. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial.
von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A.
Journal of Clinical Oncology. 2012 Jan 23. [Epub ahead of print]

49. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.
Journal of Cancer Research and Clinical Oncology. 2012 Jan;138(1):65-72. Epub 2011 Sep 30.

50. Chronische Lymphatische Leukämie (CLL).
Wendtner C, Dreger P, Gregor M, Greil R, Knauf W, Schetelig J, Steurer M, Stilgenbauer S.
Onkopedia. Jan 2012. http://www.dgho-onkopedia.de/onkopedia/leitlinien/cll

51. Panitumumab (Vectibix) eine gleichwertige Alternative zu Cetuximab (Erbitux) in der Erst, Zweit sowie Drittlinentherapie des metastasierten Kolorektalkarzinoms.
Hohla F, Greil R.
Med.ium. 1/2012, p.22-25.

52. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP.
Journal of Neuro-Oncology. 2011 Dec;105(3):613-20. Epub 2011 Jun 26.

53. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M.
Clinical Cancer Research. 2011 Oct 13. [Epub ahead of print]

54. Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
Journal of Clinical Oncology. 2011 Oct 11. [Epub ahead of print]

55. Das RANK/RANK- Ligand- System beim Mammakarzinom: biologische Grundlagen.
Mlineritsch B, Ressler S, Greil R.
Universum Innere Medizin 10/11

56. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.
Journal of Cancer Research and Clinical Oncology. 2011 Sep 30. [Epub ahead of print]

57. Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells
Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN.
PLoS One. 2011;6(8):e23758. Epub 2011 Aug 18.

58. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M.
Clinical Cancer Research. 2011 Aug 1.

59. Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.
Merkel O, Hamacher F, Sifft E, Kenner L, Greil R; for the European Research Initiative on Anaplastic Large Cell Lymphoma.
Molecular Cancer Therapeutics. 2011 Jun 28.

60. Raltegravir in pregnancy: a case series presentation.
Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, Rieger A, Zangerle R.
Int J STD AIDS. 2011 Jun;22(6):358-60.

61. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P,Hochreiner G, Forsthuber EP, Fesl C, Greil R; on behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Lancet Oncol. 2011 Jun 3. [Epub ahead of print]

62. ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.
Melchardt T, Hofbauer SW, Greil R, Hopfinger G.
Memo - Magazine of European Medical Oncology. 2011 June 1; 4(2): 120-123.

63. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, Asslaber D, Tinhofer I, Greil R, Egle A.
Leukemia. 2011 Sep;25(9):1452-8. doi: 10.1038/leu.2011.111. Epub 2011 May 24.

64. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M, Mlineritsch B, Ressler S, Moik M, Kappacher A, Rosenlechner S, Greil R.
Oncology. 2011;80(1-2):34-41. Epub 2011 May 23.

65. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I.
Cancer. 2011 May 15;117(10):2163-9. doi: 10.1002/cncr.25752. Epub 2010 Nov 18

66. Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial.
Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M.
J Clin Oncol. 2011 Jul 1;29(19):2653-9. Epub 2011 May 9.

67. Wechselbeschwerden unter antihormoneller oder Chemotherapie bei Brustkrebs.
Pircher M, Mlineritsch B, Greil R.
Med.ium. 05/2011

68. Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe.
Greil R, Borštnar S, Petráková K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K.
Onkologie. 2011;34(5):233-8. Epub 2011 Apr 26.

69. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M.
Acta Oncologica. 2011 Apr 18. [Epub ahead of print]

70. VEGF, PARP, mTOR, EGFR und PI3K beim HER2-negativen Mammakarzinom.
Gampenrieder S, Mlineritsch B, Greil R.
Universum Innere Medizin. 04/11.

71. Wie verändere ich mein Äußeres zum Positiven?
Eder S, Mlineritsch B, Greil R.
Med.ium. April 2011.

72. Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14.
Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R.
The Breast Journal. 2011 Mar 31. doi: 10.1111/j.1524-4741.2011.01073.x.

73. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.
Annals of Hematology. 2011 Feb 25. [Epub ahead of print]

74. Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT(3)NxM0, Low Rectal Cancer : A Phase II Study.
Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J; TAKO 05/ABCSG R-02 Trial Investigators the Investigators.
Strahlentherapie und Onkologie. 2011 Jan 21. [Epub ahead of print]

75. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J.
Annals of Oncology. 2011 Feb;22(2):486-7. Epub 2011 Jan 13.

76. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I.
Cancer Immunol Immunother. 2011 Jan;60(1):75-85. Epub 2010 Sep 21.

77. „Krebskranke stehen mitten im Leben“ - Interview.
Greil R.
Med.ium. Jänner/Februar 2011, S 36-38.

78. Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S, Mlineritsch B, Greil R.
Expert Review of Anticancer Therapy. 2011 Mar;11(3):333-49.

79. Complete Remission of Waldenstrom Macroglobulinemia With Azacitidine and Rituximab.
Weiss L, Melchardt T, Neureiter D, Kemmerling R, Pleyer L, Greil R, Egle A, Moshir S.
J Clin Oncol. 2011 Jul 5. [Epub ahead of print]

80. PARP-Inhibitoren.
Ressler S, Mlineritsch B, Greil R.
Universum Innere Medizin. 04/11

81. A new trisaccharide derivative from Prenanthes purpurea.
Posch M, Jöhrer K, Sezai Cicek S, Greil R, Ellmerer E, Zidorn C.
J SERB CHEM SOC, 76 (6) 841-845 (2011), JSCS-4164

82. Bisphosphonate in der Therapie des Mammakarzinoms.
Ressler S, Mlineritsch B und Greil R.
Med.ium (03): 26-30.

83. Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J.
Anticancer Research. 2011 Dec;31(12):4439-43.

84. MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.
Asslaber D, Pinon Hofbauer J, Greil R, Egle A.
Journal of Nucleic Acids Investigations. 2010, Dec 1, 1(1): 76-80.

85. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.
Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D, Tinhofer I, Aberger F, Hartmann TN, Greil R.
Oncogene. 2010 Sep 2;29(35):4885-95. Epub 2010 Jul 5.

86. Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial.
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
Journal of Clinical Oncology. 2010 Aug 16. [Epub ahead of print]

87. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma.
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
New England Journal of Medicine. 2010 Aug 12;363(7):640-652.

88. Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere((R))-based conventional chemotherapy.
Czejka M, Greil R, Ulsperger E, Schnait H, Kienesberger K, Brumnik T, Farkouh A, Schierholz J.
International Journal of Clinical Pharmacology and Therapeutics. 2010 Jul;48(7):483-4. No abstract available.

89. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R.
Blood. 2010 May 27;115(21):4191-7. Epub 2010 Jan 20.

90. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
Merkel O, Asslaber D, Piñón JD, Egle A, Greil R.
Cell Cycle. 2010 Jul 15;9(14):2764-8. Epub 2010 Jul 3.

91. 1-Liposomal cytarabine is effective and tolerable in the treatment of CBS relapse of acute lymphoblastic leukemia (ALL) and very aggressive lymphoma.
Gökbuget N, Hartog M, Bassan R, Coiffier B, Derigs HG, Dombret H, Greil R, Huguet F, Jourdan E, Junghanss C, Leimer L, Pollmeier G, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D for the German Multicenter Study Group of Adult ALL and the European Working Group on Adult ALL.
Haematologica-The Hematology Journal. 2010 in the press.

92. An uncommon cause of anaemia: Sheehan's syndrome.
Melchardt T, Namberger K, Weiss L, Egle A, Faber V, Greil R.
Wiener Klinische Wochenschrift. 2010 Dec 7.

93. Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW, Piñón JD, Brachtl G, Haginger L, Wang W, Jöhrer K, Tinhofer I, Hartmann TN, and Greil R.
Cancer Research. 2010 Sep 7. [Epub ahead of print]

94. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L.
Proceedings of the National Academy of Sciences of the United States of America. 2010 Aug 30.

95. PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.
Wasim M, Carlet M, Mansha M, Greil R, Ploner C, Trockenbacher A, Rainer J, Kofler R.
Journal of Steroid Biochemistry and Molecular Biology. 2010 Jun;120(4-5):218-27. Epub 2010 May 6.

96. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R.
Annals of Hematology. 2010 Mar;89(3):273-82. Epub 2009 Aug 20.

97. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R.
British Journal of Cancer. 2010 Oct 12;103(8):1201-8. Epub 2010 Sep 28.

98. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M, Geltner C, Auberger J, Gastl G, Mitterbauer M, Willinger B, Knöbl P, Resch G, Waldner R, Makrai A, Hartmann G, Girschikofsky M, Greil R.
International Journal of Antimicrobial Agents. 2010 Oct 12.

99. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.
Journal of Clinical Oncology. 2010 Oct 20;28(30):4635-41. Epub 2010 Sep 7.

100. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, Mühlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.
Annals of Oncology. 2010 Dec;21(12):2410-9. Epub 2010 May 13.

101. Neue Therapie in Sicht.
Merkel O, Kenner L, Greil R
SpringerMedizin. 22.09.2010

102. Aplasiestation der III. Medizin.
Russ G, Greil R
Med.ium. 05/2010, Seite 23-24.

103. Nebenwirkungen von Bortezomib.
Weiss L, Mlineritsch B, Greil R
CliniCum. 02/2010.

104. Nebenwirkungen von Azacitidin.
Melchardt T, Mlineritsch B, Greil R
Krebs:Hilfe. Krebshilfe 02/2010, Seiten 12-13.

105. Krebsmedikamente im Focus.
Gastl G, Samonigg H, Ludwig H., Greil R
krebspatienten.info

106. Chronisch Lymphatische Leukämie im Überblick.
Greil R
krebspatienten.info

107. Bewegung gegen Krebs.
Pleyer L., Kappacher A., Rosenlechner S., Greil R.
In Braumann KM., Stilller N. (Editors), Bewegungstherapie bei internistischen Erkrankungen (S. 223-240).Berlin: Springer (2010)

108. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
Greil R., Pleyer L., Neureiter D., Faber V.
Wien New York: Springer, (2010)

109. Introduction to „Classic“ Chronic Myeloproliferative Disoderes (CMPDs)- Molecular and Cellular Biology.
Pleyer L. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 1-15). Wien New York: Springer (2010)

110. Essential Thrombocythemia (ET).
Pleyer L., Faber V., Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 14-50). Wien New York: Springer (2010)

111. Polycythemia Vera (PV).
Pleyer L.,Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 51-80). Wien New York: Springer

112. Primary Myelofibrosis (PMF)
Pleyer L., Faber V., Neureiter D. and Greil R.
[Previously Chronic Idiopathic Mylofibrosis (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. (S. 81-116). Wien New York: Springer

113. Myelodysplastic Syndromes (MDS).
Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 153-222). Wien New York: Springer

114. Chronic Myelomonocytic Leukemia (CMML).
Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 223-234). Wien New York: Springer

115. Rare Clonal Myeloid Disease.
Melchardt T., Weiss L., Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 235-258). Wien New York: Springer

116. De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome).
Pleyer L. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 259-280). Wien New York: Springer

117. Clonal Bone Marrow Failure Overlap Syndromes.
Pleyer L., Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 281-288). Wien New York: Springer

118. Triple Negative Breast Cancer
Ressler S, Mlineritsch B, Greil R.
memo - Magazine of European Medical Oncology. Volume 3, Number 4, 185-189, DOI: 10.1007/s12254-010-0232-5

119. Bewegungstherapie bei internistischen Erkrankungen
Pleyer L, Kappacher A, Rosenlechner S, Greil R.
Bewegung und Krebs, 2010, II, 223-240, DOI: 10.1007/978-3-642-01332-4_17

120. Bewegung gegen Krebs - Lebensstilambulanz für Krebspatienten.
Mlineritsch B, Berer A, Greil R.
Der Salzburger Arzt , 2009 Mai, 16-19

121. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R; Austrian Breast and Colorectal Cancer Study Group.
Clinical Breast Cancer. 2009 Jun;9 Suppl 1:S18-27. Review.

122. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.
Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP.
Cancer Letters. 2009 Jan 8;273(1):127-39. Epub 2008 Sep 7.

123. Hodgkin lymphoma in Tyrol - a population-based study.
Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A.
Annals of Hematology. 2009 May;88(5):449-56. Epub 2008 Oct 10.

124. Phase II randomized neoadjuvant study of the mTOR inhibitor everolimus (RAD001) in combination with letrozole versus placebo and letrozole in patients with ER+ breast cancer
Baselga J, Semiglazov V, von Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, KubistaE, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane H, Dixon JM, Jonat W, Rugo HS
Journal of Clinical Oncology. 2009 Jun 1;27(16):2630-7. Epub 2009 Apr 20.

125. Multicenter Phase II study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First line Treatment in Elderly Patients with Metastatic Breast Cancer.
Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R, on behalf of the Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group (AGMT).
Onkologie. 2009;32(1-2):18-24. Epub 2009 Jan 20.

126. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler C, Piñón JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A.
Blood. 2009 Mar 19;113(12):2791-4. Epub 2009 Jan 23.

127. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.
Hartmann T, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Haran M, Shachar I, Burger M, Honczarenko M, Greil R, Alon R.
Cancer Research. 2009 Apr 1;69(7):3121-30. Epub 2009 Mar 17.

128. The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.
Pleyer L, Egle A, Hartmann TN, Greil R.
Nature Clinical Practice Oncology. 2009 Jul;6(7):405-18. Epub 2009 Jun 2. Review.

129. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer.
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP.
Clinical Cancer Research. 2009 Feb 15;15(4):1452-1459.

130. Randomized Phase III Trial Comparing Biweekly Infusional 5-Fluouracil/Leucovorin Alone or with Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3.
Van Cutsem E, Labianca R, Bodoky G, Barone C, Roth A, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero A, Mini E, Greil R, Di Constanzo F, Colette L, Cisar L, Zhang X, Kayat D, Bokemeyer C, Roth AD, Cunningham D.
Journal of Clinical Oncology. 2009 Jul 1;27(19):3117-25. Epub 2009 May 18.

131. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study.
Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B.
EJSO - European Journal of Surgical Oncology. 2009 Feb 26. [Epub ahead of print]

132. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.
Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R.
Journal of Immunotherapy. 2009 Apr;32(3):302-9.

133. Thalidomide-Dexamethasone compared to Melphalen-prednisolone in elderly patients with Multiple Myeloma.
Ludwig H, Hajek R, Tóthová E, Johannes Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A.
Blood. 2009 Apr 9;113(15):3435-42.

134. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E/Seifert M, Marth C, Samonigg H, Bjelic-Radisic V, Tausch C, Steger G, Greil R, on behalf of the Austrian Breast and Colorectal Cancer Study Group
New England Journal of Medicine. Feb 12;360(7):679-91

135. Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.
Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H.
Antiviral Therapy. 2009;14(8):1189-93.

136. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
Laimer M, Namberger K, Massone C, Koller J, Emberger M, Pleyer L, Hintner H, Greil R.
Acta Dermato-Venereologica. 2009 Nov;89(6):631-5.

137. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry.
Breast Cancer Research and Treatment. 2009 May;115(2):373-80. Epub 2008 Jul 26.

138. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research. 2009 Sep 15;15(18):5888-94. Epub 2009 Sep 1.

139. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN, Pleyer L, Desch P, Egle A, Greil R.
Discovering Medicine. 2009 Oct;8(42):157-64. Review.

140. The Dark Side of the Moon - The Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.
Greil R.
Breast Care. 2009; 4:144-147, Editorial.

141. Die Palliativstation an der III Medizin.
Faber V, Greil R.
Salzburger Arzt. 11/2009. Seite 24-26.

142. Stammzelltransplantation.
Namberger K , Greil R
Salzburger Arzt. 12/2009

143. Zielgerichtete Krebstherapien; Antikörpertherapie des metastasierten Kolorektalen Karzinoms.
Mlineritsch B, Kappacher A, Greil R.
Salzburger Arzt. 10/2009, Seite 19-22.

144. Rheumatoide Arthritis.
Psenak O, Studnicka-Benke A, Greil R.
Salzburger Arzt. 22. Jahrgang, Nummer 7/8, Juli/August 2009, S. 17-21.

145. Psychoonkologie an der III. Medizin
Rambause-Martinek L, Wendtner F, Greil R
Salzburger Arzt, 12/2009, Seite 20-22

146. Stammzellen: Die Kernreaktoren für das Tumorfeuer
Greil R
Österreichische Ärztezeitung 25.05.2009

147. Klinik und Labor verbinden
Greil R
Österreichische Ärztezeitung, Nr. 7, 10.04.2009

148. Die Bedeutung von JAK2 in der Pathogenese
Pleyer L, Greil R
JATROS, 05/2009, Seite 26-30

149. Klassische myeloproliferative Erkrankungen: Die Bedeutung von JAK2 in der Pathogenese.
Pleyer L, Greil R
JATROS Haematologie und Onkologie 05/2009 (Pleyer L, Greil R)

150. Technologien der Stammzellgewinnung
Namberger K , Greil R
Krebs:hilfe Heft 6:2009

151. SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.
Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I.
Blood. 2008 Sep 1;112(5):2168; author reply 2169. No abstract available.

152. Capecitabin (Xeloda) - Wirksam beim metastasierten Mammakarzinom.
Greil R.
Krebshilfe. 5:2008 Seite /7

153. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eichenberger K, Greil R, Tinhofer I.
Journal of Clinical Oncology. 2008 May 10; 26(14):2252-7.

154. Is Chemoendocrine Treatment without Alternative? Editorial.
Greil R.
Breast Care. 2008, 3:231-235.

155. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Lancet Oncology. 2008 Sep;9(9):840-9. Epub 2008 Aug 19.

156. Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).
Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J.
Anticancer Research. 2008 Sep-Oct;28(5B):2901-5.

157. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications.
Greil R, Psenak O, Roila F.
Ann Oncol. 2008 May; 19Suppl 2:ii116-8.

158. Erythropoietins in cancer patients: ESMO Recommendations for use.
Greil R, Thödtmann R, Roila F.
Ann Oncol. 2008 May;19 Suppl 2:ii113-5.

159. Diagnostic Algorithms, Monitoring, Prognostication and Therapy in Chronic Myeloid Leukemia (CML) A Proposal of the Austrian CML Platform.
Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G.
Wiener Klinische Wochenschrift. 2008 Nov;120(21-22):697-709.

160. Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
Arkenau H-T, Graeven U, Stephan Kubicka, Axel Grothey, Christina Englisch-Fritz, Albrecht Kretzschmar, Greil R, Werner Freier, Thomas Seufferlein, Axel Hinke, Hans-Joachim Schmoll, Wolff Schmiegel, Rainer Porschen, on Behalf of the AIO Colorectal Study Group
Clinical Colorectal Cancer. January 2008, 60 - 64.

161. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M.
Annals of Oncology. 2008 Jul;19(7):1266-70. Epub 2008 Mar 11.

162. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research. 2008 Apr 1;14(7):2082-7.

163. A phase I/II study of bortezomib and capezitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid P, Kuehnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K.
Annals of Oncology. 2008 May;19(5): 871-6. Epub 2008 Jan 21.

164. Expertenstatement Medikamentöse Therapie bei Magenkarzinom.
Wöll E, De Vries A, Eisterer, Greil R, Hejna M, Keil F, Stein H, Zacherl J.
Anticancer Research. 2008 Mar-Apr;28(2B):1213-9. Review.

165. Cyclin D1 expression in breast cancer and tamoxifen therapy.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W., Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant M, Filipits M, for the Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research.2008;14(6) March 15 1767 - 1774.

166. Der Tod als Tabu, Wissensdefizit und Kostenfaktor - Der Umgang der Medizin mit der Transition von Leben und Tod.
Greil R.
in Ethik im Sog der Ökonomie (Michael Fischer/Ingeborg Schrems) 2008, Seite 181 - 195

167. Wert und Kosten von Leben und Tod in der Medizin. Der Verteilungskampf in und um die Medizin und die ethischen Auswirkungen auf Individuum und Gesellschaft
Greil R.
In Weingartner P. (Editor) Rohstoff Mensch, das flüssige Gold der Zukunft? Ist Ethik privatisierbar? (S.83 - 118) Frankfurt: Peter Lang

168. Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.
Merkel O, Heyder C, Asslaber D, Hamacher H, Holler C, Stöcher M, Tinhofer I, Greil R.
Journal of Molecular Medicine-JMM. 2008 May;86(5):541-52. Epub 2008 Feb 23.

169. Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis.
Neureiter D, Kemmerling R, Ocker M, Seidlhofer C, Faber V, Stöcher M, Greil R, Dietze O.
Journal of Hematopathology. 2008 Jul;1(1):23-7. Epub 2008 Apr 19.

170. Tumour-immune cell interactions modulated by chemokines.
Jöhrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R.
Expert Opinion on Biological Therapy. 2008 Mar;8(3):269-90. Review.

171. Tag der Darmgesundheit in Salzburg
Greil R
Magazin des Vereins für Darmkrebsinformation, Ausgabe 2/2008

172. The Role of Imaging in Malignant Lymphoma: A critical View on PET Scanning in Current Clinical Practice.
Namberger K, Greil R.
Imaging Decisions. 4/2007 22 - 31.

173. ASCO 2007 Neue Daten aus Chicago.
Greil R.
IATROS Haematologie und Onkologie. 03/2007 66-67

174. Hematopoietic growth factors: ESMO Recommendations for the application.
Psenak O, Greil R.
Annals of Oncology. 18 (Supplement 2): ii89 - ii91, 2007.

175. Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S.
Wiener Klinische Wochenschrift. 2007;119(7-8):259-66. Review. German. No abstract available.

176. Fulvestrant (Falsodex) in heavily pretreated postmenopausal patients with advanced breast cancer: Single centre clinical experience from the compassionate use programme.
Mlineritsch B, Psenak O, Mayer P, Moik M, Hauser-Kronberger C, Greil R.
Breast Cancer Research and Treatment. 2007 Nov;106(1):105-12. Epub 2007 Feb 13.

177. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group.
Journal of Clinical Oncology. 2007 Sep 20;25(27):4217-23. Epub 2007 Jun 4.

178. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14.
Journal of Clinical Oncology. 2007 May 20;25(15):2012-8.

179. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.
Journal of the National Cancer Institute. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11.

180. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M; Austrian Breast and Colorectal Cancer Study Group-07.
Breast Cancer Research and Treatment. 2008 Nov;112(2):309-16. Epub 2007 Dec 14.

181. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).
Breast Cancer Research and Treatment. 2008 Nov;112(1):203-13. Epub 2007 Dec 22

182. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group.
British Journal of Cancer. 2007 Oct 22;97(8):1021-7. Epub 2007 Sep 25.

183. Erythropoietins in cancer patients: ESMO recommendations for use.
Greil R, Thödtmann R, ESMO Guidelines Working Group.
Annals of Oncology. 2007 Apr; 18 Suppl 2:ii86-8.

184. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?
Greil R, Stein HJ.
Lancet Oncology. 2007 Mar;8(3):189-90.

185. Massive Bone Marrow Infiltration in Colon Carcinoma after Therapy with Activated Protein C.
Pleyer L, Went P, Russ G, Prinz E, Faber V, Röwert HJ, Karlbauer R, Greil R.
Wiener Klinische Wochenschrift. 2007;119(7-8):254-8.

186. Morbus Hodgkin.
Greil R.
in Lymphoproliferative Erkrankungen R.Greil Uni-Med Science, 2007, Seite 43,67

187. Entwicklungen und Perspektiven in der Behandlung der Lymphatischen Neoplasien.
Pleyer L, Desch P, Greil R.
in Lymphoproliferative Erkrankungen R.Greil Uni-Med Science 2007, Seiten 139-155.

188. Regulation of apoptosis.
Pleyer L, Tinhofer I, Greil R.
in ESMO Handbook of principles of translational Research Hakan Mellstedt, Dirk Schrijvers, Dimitrios Bafaloukos, Richard Greil Informa healthcare 2007, Seite 67 - 69

189. Dasatinib
Pleyer L, Greil R
Arzneimittelprofil Medizin Medien Austria, 11/2007 pp 1-16

190. Herpesvirusinfektionen beim Tumorpatienten am Beispiel des Multiplen Myeloms
Pleyer L, Greil R
MMagazin Extra 1, 09/2007

191. Erklärung der Studienvorteile: Schwedisch-österreichische Studie (SÖS) für PatientInnen mit Brusktrebs startet
Greil R
Krebs:hilfe 0672007

192. The Role of Imaging in Malignant Lymphoma: A critical View on PET Scanning in Current Clinical Practice
Namberger K, Greil R
Imaging Decisions, 4/2007 Seite 22 - 31

193. Adjuvanter Einsatz von Trastuzumab (Herceptina) in der klinischen Praxis außerhalb von klinischen Studien.
Greil R, H.J.Senn, Thörlimann B, Minckwitz G.v., Herrmann R, Jakesz R, Gnant M.
BREAST CARE, 2006; 1:96-101.

194. Diagnose und Therapie der Plasmazelldyskrasien.
Greil R.
Der Salzburger Arzt. 20. Jg, Nr.4 April 2006: 23-29.

195. Sorafenib (Bay 43-9006 (Sorafenib, Nexavar®), Pathopyhsiologie und klinische Anwendung für zielgerichtete Therapie)
Greil R.
Arzneimittelprofil, Dezember 2006, 3 - 15

196. Alemtuzumab (MabCampath) - Interview.
Greil R.
Krebs:Hilfe, 2006.

197. Klinische Praxis Aromataseinhibitoren: Upfront, Switch oder Extended?
Harbeck N, Jakesz R, Greil R, Jonat W, Maass N, Kaufmann M, Ortmann O, Possinger K, Steger G.
Breast Care. 2006: 1:37-43.

198. Neueste Therapien und intensive Forschung im Kampf gegen Krebs.
Greil R.
Salzburger Fenster, September 2006 SF30/2006 Seite 15.

199. Gut begleitet.... Ist Sterben in Würde möglich? - Interview.
Greil R.
Salzburger Fenster. September 2006 SF 30/2006 Seite 9.

200. Sorafenib (Nexavar) - Ein großer Gewinn für die Onkologie - Interview.
Greil R.
krebs:hilfe, 6:2006

201. Erlotinib beim nicht-kleinzelligen Lungenkrebs.
Greil R.
Ärztekrone. 27. Oktober 2006

202. The still long and winding road to neoadjuvant systemic therapy (NST) as the standard of care and to the achievement of its prophecied goals in breast cancer - The con position.
Greil R.
Breast Care. 2006; 352-357. (Editorial)

203. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature.
Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R.
Leukemia and Lymphoma. 2006 Aug;47(8):1683-5

204. Purine antagonists for chronic lymphocytic leukaemia.
Steurer M, Pall G, Richard S, Schwarzer G, Bohlius J, Greil R, on behalf of the Cochrane Haematologic Malignancies Group
Cochrane Database of Systematic Reviews. 2006 Jul 19;3:CD004270.

205. Wie sterben wir? Wie schön ist der Tod? Wie teuer ist der Tod? - Die Palliativmedizin im Spannungsfeld der Ressouercenallokation
Greil R.
in Medizin- und Bioethik, Ethik transdisziplinär Frankfurt a.M.: Peter Lang Europäischer Verlag der Wissenschaften 2006, Seite 351 - 370

206. The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer I, Steurer M, Leitinger G, Rumpold H, Egle A, Erdel M, Greil R.
Haematologica-The Hematology Journal. 2006 Sep;91(9):1291-3.

207. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R.
Blood. 2006 Nov 1;108(9):2950-6. Epub 2006 Jul 6.

208. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer C, Jöhrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M.
Cancer Immunology Immunotherapy. 2006 Oct;55(10):1228-37. Epub 2006 Jan 28.

209. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R; Cochrane Haematologic Malignancies Group.
Cancer Treatment Reviews. 2006 Aug;32(5):377-89. Epub 2006 Jun 21. Review.

210. A role of TRAIL in killing osteoblasts by myeloma cells.
Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R.
FASEB Journal. 2006 Apr;20(6):759-61. Epub 2006 Jan 25.

211. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R.
Cancer. 2006 Nov 15;107(10):2408-16.

212. Adjuvante und neoadjuvante Therapie des Pankreaskarzinoms.
Greil R.
Krebs:Hilfe, 1/05 S 34-36

213. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients.
Fey MF, Greil R, Jost LM.
Annals of Oncology. 2005 May;16 Suppl 1:i48-i49

214. Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W.
Annals of Hematology. 2005 Apr;84(4):217-22. Epub 2004 Nov 6.

215. ESMO recommendations for the application of hematopoietic growth factors.
Greil R, Jost LM.
Annals of Oncology. 2005;16 Suppl 1:i80-2.

216. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG.
The Lancet. 2005 Aug 6-12;366(9484):455-62.

217. Continuous prednisolone versus conventional prednisolone with VMCP-Interferon-a2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tar-Kovacs G, Linkesch W, Maniatis A, Morant R, Schüller J, Niessner H, Preis P, Drach J, Schuster J.
British Journal of Haematology. 2005 Nov;131(3):329-37.

218. Diffuse large B cell lymphoma (DLBCL) as a second, non-clonal lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS): case report and review of the literature.
Mian M, Tzankov A, Psenak O, Greil R, Fiegl M.
Leukemia & Lymphoma. 2006 May;47(5):940-3.

219. Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities.
Zidorn C, Johrer K, Ganzera M, Schubert B, Sigmund EM, Mader J, Greil R, Ellmerer EP, Stuppner H.
Journal of Agricultural and Food Chemistry. 2005 Apr 6;53(7):2518-2523.

220. 1,10-Epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae)
Zidorn C, Ellmerer EP, Konwalinka G, Ongania KH, Schwaha R, Greil R, Jöhrer K, Perry NB, Stuppner H
Letters in Organic Chemistry. Volume 2, Number 5, August 2005 , pp. 461-464(4).

221. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia.
Hallek M, Stahel RA, Greil R.
Annals of Oncology. 2005 May;16(suppl_1):i50-i51. No abstract available

222. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma.
Harrouseau JL, Greil R, Kloke O.
Annals of Oncology. 2005;16 Suppl 1:i45-7.

223. Die (neo)adjuvante Therapie des Pankreascarcinoms.
Greil R.
Krebs :Hilfe 2/2005

224. Chemotherapie im Alter.
Greil R, Faber V.
in Lebensqualität im Alter Springer Verlag 2005

225. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Höltl L, Bartsch G, Greil R, Thurnher M.
Clinical Cancer Research. 2005 Apr 1;11(7):2459-65.

226. Der Stellenwert der Hormontherapie in der Behandlung des Mammacarcinoms.
Greil R.
Der Salzburger Arzt, Seite 30-34, Juni 2004.

227. Neoadjuvante und adjuvante Therapiekonzepte: Paradigmenwechsel beim Bronchuscarcinom?
Greil R.
IATROS Pulmonologie. 14-17, 3/2004.

228. Das Prostatcarcinom des älteren Mannes aus der Sicht des internistischen Onkologen.
Greil R.
KREBSHILFE, geriatrische Onkologie, 2/04 26-28.

229. Editorial zur adjuvanten und neoadjuvanten Therapie des NSCLC.
Greil R.
Iatros, Pulmonologie, 3, 3/2004.

230. Früherkennung von Tumorerkrankungen.
Greil R.
Ärztekrone. Sonderausgabe Juli 2004 (5/2004): 4-6.

231. Biomarkers in non-small cell lung cancer prevention.
Hilbe W, Dirnhofer S, Greil R, Wöll E.
European Journal of Cancer Prevention. 2004 Oct;13(5):425-36.

232. Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?
Holzner B, Fischhofer M, Kemmler G, Kopp M, Sperner-Unterweger B, Krugmann, J, Dirnhofer S, Greil R.
European Journal of Haematology. 2004 Nov;73(5):318-24.

233. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr.
Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R.
European Journal of Haematology. 2004 Jun;72(6):381-9.

234. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1.
Jöhrer K, Janke K, Krugmann J, Fiegl M, Greil R.
Clinical Cancer Research. 2004 Mar 15;10(6):1901-10.

235. Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas.
Krugmann J, Tzankov A, Dirnhofer S, Fend F, Greil R, Siebert R, Erdel M.
Journal of Clinical Pathology. 2004 Apr;57(4):360-364.

236. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group.
Annals of Oncology. 2004 Feb;15(2):276-82.

237. Das Prostatcarcinom des älteren Mannes aus der Sicht des internistischen Onkologen.
Greil R.
ONKO-LOGISCH, 2004, in press = nicht p.r. Zeitschrift, KREBSHILFE 2/04, 26-28.

238. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer W, Bechter O, Söderberg O, Nilsson K, Terol M, Greil R, Thaler J, Herold M, Finke L, Günthert U, Montserrat E, Stauder R.
Leukemia Research. 2004 Oct;28(10):1043-51.

239. Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors.
Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B.
Acta Oncologica. 2004;43(2):153-60.

240. Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway.
Anether G, Tinhofer I, Senfter M, Greil R.
Blood. 2003 Jun 1;101(11):4561-8. Epub 2003 Jan 30.

241. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.
Greil R, Anether G, Johrer K, Tinhofer I.
Journal of Leukocyte Biology. 2003 Sep;74(3):311-30. Review.

242. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J, Tzankov A, Gschwendtner A, Fischhofer M, Greil R, Fend F, Dirnhofer S.
Modern Pathology. 2003 Jun;16(6):566-73.

243. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group.
Leukemia Research. 2003 May;27(5):405-11.

244. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S.
Clinical Cancer Research. 2003 Apr;9(4):1381-6.

245. Tuning the rheostat of the myelopoietic system via Fas and TRAIL.
Greil R, Anether G, Johrer K, Tinhofer I.
Critical Reviews in Immunology. 2003;23(4):301-22. Review.

246. Adulte Stammzellen - Eine Alternative?
Greil R.
in Science and Society, Vol. 1 Seismo Verlag, Zürich, pp.116

247. The multimodality treatment of pancreatic cancer: Current status and further perspectives
Greil R
EUROPEAN SURGERY (ACTA CHIRURGICA AUSTRIACA), 34,42-57, 2002

248. The role of soluble CD23 in differentiation between stable and progressive forms of B CLL.
Schwarzmeier JD, Shehata M, Berger R, Marschitz I, Hilgarth M, Hubmann R, Louda N, Greil R
LEUKEMIA AND LYMPHOMA, 43(3),549-555,2002

249. The impact of hemoglobin levesl on fatigue and quality of life in cancer patients.
Holzner B, Greil R, Kemmler G, Kopp M, Zeimet G, Raderer M, Hejna M, Zöchbauer S, Krajnik G, Huber H, Sperner-Unterweger B.
ANNALS OF ONCOLOGY,13,965-973, 2002

250. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended field radiotherapy in intermediate stage Hodgkin's lymphoma: final results of the german Hodgkin Lymphoma study Group Trial HD5
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V
JOURNAL OF CLINICAL ONCOLOGY, 20,476-484,2002

251. High grade B cell lymphoma with infiltration-associated peripheral neuropathy and paraneoplastic myopathy: report of a case
Fiegl M, Muigg A, Dirnhofer S, Greil R
LEUKEMIA AND LYMPHOMA, 43(8),1687-1690, 2002

252. Intravascular large B cell lymphoma with a fulminant clinical course: a case report with definitive diagnosis post mortem
Fiegl M, Greil R, Krugmann J, Pechlaner C, Krugmann K, Dirnhofer S
ANNALS OF ONCOLOGY, 13(9), 1503-1506, 2002

253. Letter to the Editor of the New England J Medicine, referrig to "a long term study of prognosis in monoclonal gammopathy of undetermined significance" by Kyle et al., 2002.
Fiegl M, Greil R
NEW ENGLAND JOURNAL OF MEDICINE, Letter to the Editor, 346, (26) 2087, 2002

254. Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.
Tinhofer I, Anether G, Senfter M, Pfaller K, Bernhard D, Hara M, Greil R.
FASEB J. 2002 Aug;16(10):1295-7. Epub 2002 Jun 7.

255. Multidimensional scaling as a tool for analyzing quality of life data
Kemmler J, Holzner B, Kopp M, Dünser M, Greil R, Hahn E, Sperner-Unterweger B:
QUALITY OF LIFE RES 11, 223-233,2002

256. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.
Crazzolara R, Jöhrer K, Johnstone RW, Greil R, Kofler R, Meister B, Bernhard D.
Br J Haematol. 2002 Dec;119(4):965-9.

257. Pulmonale Toxizität von Zytostatika
Greil R
ONKO-LOGISCH, 2002 Eingeladene Publikation

258. Splenectomy versus Medical Treatment for Idiopathic Thrombocytopenic Purpura
Gadenstätter M, Lamprecht B, Klingler A, Wetscher GJ, Greil R, Schmid T
AMERICAN J SURGERY, 184, 606-610, 2002.

259. Mehr Gesundheit durch mehr Information. Moderationsbeitrag zu den Gesundheitsgesprächen des Europäischen Forums Alpbach.
Greil R
Sonderband der Schriftenreihe:" Gesundheit-Mensch-Gesellschaft Rudolf Trauner Universitätsverlag. Im Druck.2002

260. Reactivity of anti-platelet monoclonal antibodies with committed megakaryocytic precursor cells, platelets and megakaryocytes.
Geissler D, Greil R, Thaler J, Konwalinka G, Schulz TF, Gattringer C, Huber H
LEUCOCYTE TYPING II, P 1.14, 784-787, 1987 1987

261. Prognose und Therapie der hämatologischen Neoplasien und solider Tumoren im Alter
Greil R
FORTBILDUNGSKOMPENDIUM DER ÖSTERREICHISCHEN ÄRZTEKAMMER ZUM THEMA GERIATRIE In: Grundlagen der Geriatrie: Böhmer F, Rhomber HP, Weber E

262. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether G, Marschitz I, Tinhofer I, Greil R.
Blood, 2002 Jan 15;99(2):722-3.

263. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by bcl-2.
Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, Kofler R, Csordas A, Greil R
THE FASEB JOURNAL, 2001 Jul;15(9):1613-5

264. Primary gastrointestinal MALT lymphoma. A clinicopathological and immunohistochemical study of 61 cases.
Krugmann J, Dirnhofer S, Gschwendtner A, Berresheim U, Greil R, Krugmann K, Fend F:
PATHOLOGY RESEARCH AND PRACTICE, 197,385-393,2001

265. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts.
Bernhard D, Skvortsov S, Tinhofer I, Hübl H, Greil R, Csordas A, Kofler R.
Cell Death Differ. 2001 Oct;8(10):1014-21.

266. Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J.
Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8.

267. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V.
J Clin Oncol. 2001 Jun 1;19(11):2905-14.

268. Epstein-Barr Virus associated extranodal cytotoxic NK/T-cell lymphoma of the hypopharynx in a renal allograft recipient: case report and review of literature
Stadelmann S, Fend F, Moser P, Obrist P, Greil R, Dirnhofer S
MODERN PATHOLOGY, Nov;32(11):1264-8,2001

269. Quality of life measurement in oncology--a matter of the assessment instrument?
Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, Dünser M, Margreiter R, Marschitz I, Nachbaur D, Fleischhacker WW, Greil R.
Eur J Cancer. 2001 Dec;37(18):2349-56.

270. Notfälle in der Onkologie. Akutsituationen im Ãœberblick
Greil R
ONKOLOGISCH, 3, 10-13, 2001

271. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques
Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 113,219-229, 2000

272. Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Tinhofer I, Marschitz I, Henn T, Egle A, Greil R
Blood, 2000 Jan 15;95(2):610-618.

273. Gastric cancer cell lines lack Fas Ligand (FasL) expression but kill T cells via a FasL-independent pathway.
Tinhofer I, Wykypiel H, Marschitz I, Henn T, Greil R.
GUT, 2000 May;46(5):738-740.

274. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.
Bernhard D, Tinhofer I, Tonko M, Hübl H, Ausserlechner MJ, Greil R, Kofler R, Csordas A.
Cell Death Differ. 2000 Sep;7(9):834-42.

275. Vinorelbine/Gemictabine in advanced Non-Small-Cell lung cancer (NSCLC): An AASLC Phase II trial
Krajnik G, Mohn-Staudner A, Thaler J, Greil R, Schmeikal S, Marhold F, Deutsch J, Preiss P, Malayeri R, Wein W, Huber H, Pirker R
ANNALS OF ONCOLOGY,11, 993-998, 2000

276. Leukämien und Lymphome
Greil R
ONKO-LOGISCH, 8. Jahrgang, Nr.2 , 20-23, 2000

277. Neurologische Komplikationen hämatologischer (Tumor)-Erkrankungen - Klinische Symptomatik und Therapie
Greil R
ONKO-LOGISCH, Neuroonkologie, Informationsreihe der österreichischen Krebshilfe-Krebsgesellschaft, 7. Jahrgang, Nr.2/99, 61-64.

278. Thymic Hodgkin's disease
Krugmann J, Feichtinger H, Greil R, Fend F
PATHOLOGY RESEARCH AND PRACTICE, 195 (10): 681-687, 1999.

279. Quality of life in patients with Hodgkin's disease: impact of study participation and treatment modality.
Greil R, Kopp M, Holzner B, Buchowski A, Kemmler G, Oberaigner W, Fritsch E, Rüffers U, Dirnhofer S, Diehl V, Sperner-Unterweger B
EUROPEAN JOURNAL OF CANCER, 35, 698-706,1999

280. Synergistic action of protein kinase C q and calcineurin is sufficient for Fas ligand expression and induction of a Crm-A-sensitive apoptosis pathway in Jurkat T cells
Villunger A, Ghaffari-Tabrizi N, Tinhofer I, Krumböck N, Bauer B, Schneider T, Kashibatla S, Greil R, Überall F, Green R, Baier G
EUROPEAN JOURNAL OF IMMUNOLOGY, 29 (11):3549-3561, 1999

281. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G, Holzner B, Kopp M, Dünser M, Margreiter R, Greil R, Sperner-Unterweger B.
J Clin Oncol. 1999 Sep;17(9):2932-40.

282. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R.
British Journal of Haematology. 1998 Sep;102(4):1069-80.

283. Urticaria pigmentosa - is it a systematic disease? A clinical, hemathopathological and serological study of 30 adult patients
Topar G, Staudacher C, Geisen F, Fend F, Herold M, Greil R, Fritsch P, Sepp N
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109, 279-285

284. Lower leg ulcers associated with long-term hydroxyurea therapy
Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P:
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,39, 372-374, 1998

285. Primäre und sekundäre Lymphome des Gastrointestinaltraktes: Chemotherapie im primären, adjuvanten und palliativen Einsatz.
Greil R
ACTA CHIRURGICA AUSTRIACA, 5, 274-281, 1998.(nunmehr EUROPEAN SURGERY)

286. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas(Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I, Marschitz I, Egle A, Henn T, Villunger A, Greil R.
Blood. 1998 Jun 1;91(11):4273-81.

287. Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial
Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, Zöchbauer S, Huber H, Pirker R:
EUROPEAN JOURNAL OF CANCER, 34(12),1977-1980, 1998.

288. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J.
Leuk Res. 1998 Oct;22(10):881-6.

289. Hämatopoetische Wachstumsfaktoren: Kritische Analyse des Einsatzspektrums in der klinischen Praxis
Greil R
ONKOLOGIE, 21,527-532,1998

290. The role and significance of Fas(Apo-1/CD95) ligand (FasL) expression in immune priviledged tissues and cancer cells using multiple myeloma as a model
Greil R, Egle A, Villunger A
LEUKEMIA AND LYMPHOMA, Invited review, 31 (5-6), 477-490, 1998.

291. Onkologie. Ambulante onkologische Rehabilitation in Tirol. EIN KONZEPTVORSCHLAG
Greil R
In: Ambulante Rehabilitation, Bestandsaufnahme und Entwicklungserfordernisse, Kapitel 2.9, p48-61, 1998, Herausgeber: Univ. Prof. Dr. Aichner, Tiroler Verein zur Förderung der soz. Med. Betreuung und Rehabilitation

292. Systemische Mastozytosen
Sepp N, Topar G, Staudacher Ch, Geisen F, Gabl Ch, Fend F, Herold M, Greil R, Fritsch
In:. DERMATOLOGIE. LEITLINIEN UND QUALITÄTSSICHERUNG FÜR DIAGNOSTIK UND THERAPIE Berichte von der 39. Jahrestagung der Deutschen Dermatologischen Gesellschaft Garbe C, Rassner G. Herausgeber Springer Verlag. Berlin Heidelberg New York, 1998, p 413-

293. Vinorelbine/gemictabine in advanced non-small cell lung cancer: an AASLC phase II trial
Krajnik G, Malayeri R, Thaler J, Mohn-Staudner A, Greil R, Schmeikal S, Marhold F, Deutsch J, Preiss P, Zoechbauer-Mueller S, Huber H, Pirker R
In: 11TH INTERNATIONAL CANCER CONGRESS, Rio de Janeiro (Brazil), August 24-28, 1998 Editors: Marcos Moraes, Ricardo Brentani, Ruy Bevilacqua , Monduzzi Editore, Bologna, 647-649

294. Necrotizing vasculitis associated with hepatitis C infection: successful treatment of vasculitis with interferon alpha despite persistence of mixed cryoglobulinemia.
Sepp NT, Umlauft F, Illersperger B, Grünewald K, Greil R, Vogel W
REVIEW SERIES HEPATITIS, Issue 2, 14-15, 1997

295. Reduced oxidative burst of neutrophils in MDS: Identification of two subtypes by using FMLP and PMA.
Zabernigg A, Hilbe W , Eisterer W, Greil R, Ludescher C, Thaler J
LEUKEMIA AND LYMPHOMA, 27,137-143, 1997

296. Interferon-alpha-2c and LD-Ara-C for the treatment of patients with CML: preliminary results of the Austrian multicenter phase II study
Thaler J, Hilbe W, Apelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhard M, Michlmayr G, Niessner H, Abrederis K, Geissler D, Hausmaningfer H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M
LEUKEMIA RESEARCH, 21, 75-80, 1997

297. The Interleukin-1b-converting enzyme inhibitor crmA prevents Apo-1/fas- but not glucocorticoid-induced ADP(Ribosyl)transferase cleavage and apoptosis in lymphoblastic leukemia cells
Geley S, Hartmann L, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R
FEBS LETTERS, 402,36-40, 1997

298. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R.
Br J Haematol. 1997 May;97(2):418-28.

299. Constitutive expression of Fas (Apo-1/C95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance
Villunger A, Egle A, Marschitz A, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R:
BLOOD, 1997, 90, 12-20. [Rapid Publication]

300. Fludarabin-induced apoptosis is mediated via Caspase I but is independent from Fas (Apo-1/CD95) signaling in T-acute lymphatic leukemia cells.
Villunger A, Egle A, Kos M, Böck G, Hartmann B, Geley S, Kofler R, Greil R
CANCER RESEARCH, 1997, 57, 3331-3334. [Advances in Brief]

301. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial of the Austrian Working Group for Medical Tumor Therapy
Fridrik A, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubeuer M, Helm W, Dittrich C, Faceny B, Hudec M, Radaskiewicz T, Bettelheim P
ANNALS OF HEMATOLOGY, 75,135-140,1997

302. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for neoplastic growth by antibody strategies
Villunger A, Egle A, Kos M, Hittmair T, Maly K, Greil R
INTERNATIONAL JOURNAL CANCER,65, 498-505, 1996

303. Effect of 2`, 2`- difluorodeoxycytidine (Gemcitabine) on myeloma cell lines resistant to steroids
Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R
STEM CELLS, 14, 351-362, 1996

304. Staging von Lymphomen
Greil R
ONKOLOGISCH 2, 8-10, 1996

305. IL-10 serum levels in B-cell chronic lymphocytic leukaemia.
Egle A, Marschitz I, Posch B, Herold M, Greil R.
Br J Haematol. 1996 Jul;94(1):211-2.

306. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R.
Eur J Immunol. 1996 Dec;26(12):3119-26.

307. Gastric malt lymphoma with crystalline immunoglobulin inclusions and secondary immunoblastic lymphoma in a cervical lymph node.
Fend F, Gabl C, Hittmair A, Greil R, Feichtinger H.
Pathol Res Pract. 1995 Oct;191(10):1053-8.

308. Necrotizing vasculitis associated with hepatitis C virus infection and mixed cryoglobulinaemia type II: successful treatment of vasculitis with interferon-a. Short report
Sepp N, Umlauft F, Illersperger B, Grünewald K, Schuler G, Greil R, Vogel W
DERMATOLOGY,191, 43-45, 1995

309. Recombinant human erythropoietin in the anemia associated with multiple myeloma or Non-Hodgkin's lymphoma: dose finding and identification of the predictors of response
Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B
BLOOD, 86, 4446-4453, 1995

310. Multimodal therapy in life-threatening cerebral lupus erythematosus: the benefit of cerebrospinal fluid pheresis
Pfausler B, Bösch S, Grubwieser G, Vollert H, Greil R, Hagn C, Schmutzhard E
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 107, 592-594, 1995

311. Differential regulation of adhesion molecules important for the homing process in B and T cell lymphomas of the skin and in myeloma lines
Sepp N, Stanzl U, Ransmayr G, Kos M, Greil R
In: White cell differentiation antigens, LEUKOCYTE TYPING V, Vol.2, E6.21, p 1831-1833 Editors: Schlossmann SF, Boumsell L,Gilks W, Harlan JM, Kishimoto T, Morimura C, Ritz J, Shaw S, Silverstein T, Spitzer T, Tedder TF, Todd RF. 1995.

312. Lupus Erythematodes
Sepp N, Greil R, König P
ÖSTERREICHISCHE ÄRZTEZEITUNG, 25.Juni, 12, 23-30, 1994

313. Apoptosis and therapy of malignant diseases of the hematopoietic system. Invited paper
Gruber J, Greil R
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. 105, 368-373, 1994

314. Hämatologische Notfälle
Greil R
In: INTERNISTISCHE NOTFALLSMEDIZIN. In Herausgeber: Ledochowski M, Lechleitner P Thieme Verlag, p. 70-78, 1994

315. In situ-Hybridisierung: Anwendungspotential und methodische Durchführung.
Greil R
In: DIAGNOSTISCHE HÄMATOLOGIE - METHODEN Herausgeber: Huber H, Löffler H, Faber V

316. The application of G-CSF and GM-CSF as an adjunct to chemotherapy in clinical practice: perspectives and challanges
Greil R
ONKOLOGIE, 16: 310-328, 1993, invited review

317. Long-term survival after neuroaxial irradiation of a patient presenting with extensive meningeal involvement as the primary manifestation of a systemic small-cell lymphocytic lymphoma. [letter]
Soucek D, Ransmayr G, Twerdy K, Zwirzina, Greil R, Fritsch E, Maier R, Pallua A, Gerstenbrand F
BRITISH JOURNAL OF HAEMATOLOGY, 83: 674-675, 1993

318. Investigation of nuclear c-myc oncoprotein expression in human hematopoiesis: suitability of a rapid and reliable semiquantitative evaluation system
Greil R, Fasching B, Loidl P, Weger A
LABORATORY INVESTIGATION, 62, 251-260, 1992

319. Zytostatika: Wirkungsmechanismen und Anwendungen
Greil R
ÖSTERREICHISCHE KRANKENHAUSZEITSCHRIFT, VOL 1/2, JAHRGANG 33, 39-48, 1992

320. Nuclear proto-oncogene homologous proteins during the cell cycle of physarum polycephalum
Lopez R, Lang S, Loidl A, Fasching B, Greil R, Loidl P
CELL BIOLOGY INTERNATIONAL REPORTS, 16, 1185-1191, 1992

321. Differential expression of the c-myc mRNA and c-MYC protein during terminal neoplastic B cell differentiation
Greil R, Loidl P, Fasching B, Huber H
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, Vol.: 182, 215-221, 1992 (invited Paper).

322. Morbus Hodgkin
Huber H, Greil R, Fasching B, Diehl V
In: LABORATORIUMSDIAGNOSTIK HÄMATOLOGISCHER ERKRANKUNGEN, Editors: Huber H. und Löffler H. Springer Verlag, Berlin, Heidelberg, New York, 1992

323. Single cell investigation of c-myc mRNA expression in B cell chronic lymphocytic leukemia
Greil R, Fasching B
In: RECENT ADVANCES IN CELLULAR AND MOLECULAR BIOLOGY, from the 1st World Congress of Cellular and Molecular Biology Paris, 1991. Editor: R. Wegmann, Vol.: 2, p. 95-102, 1992

324. Analysis of nuclear c-MYC oncoprotein expression: suitability of a semiquantitative evaluation system based on computer-assisted image analysis (CAS).
Greil R, Weger A, Fasching B, Loidl P
In: RECENT ADVANCES IN CELLULAR AND MOLECULAR BIOLOGY, from the 1st World Congress of Cellular and Molecular Biology Paris 1992, Editor: R. Wegmann, Vol. 6: 63-69, 1992.

325. c-myc proto-oncogene expression in multiple myeloma and chronic lymphocytic leukemia: An in situ analysis
Greil R, Fasching B, Loidl P, Huber H
BLOOD, 78, 180-191, 1991

326. Immunohistology for quantification of normal bone marrow lymphocyte subsets [letter]
Thaler J, Dietze O, Faber V, Greil R, Gastl G, Ho AD, Huber H
BRITISH JOURNAL OF HAEMATOLOGY, 73, 576-577, 1989

327. Molekularzytologischer Nachweis der Onkogenexpression: Möglichkeiten und Aussichten in der Hämato-Onkologie
Greil R, Fasching B, Huber H
ACTA MEDICA AUSTRIACA, 1, 6-11, 1990

328. A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of TNF-alpha, IFN-gamma and IL-1
Geissler D, Gaggl S, Möst J, Greil R, Herold M, Dierich M
EUROPEAN JOURNAL OF IMMUNOLOGY, 20: 2591-2596, 1990

329. Urticarielle Vaskulitis als Symptom des Muckle-Wells Syndroms
Grassegger A, Greil R,Feichtinger J, Fritsch P, Hintner H
HAUTARZT, 42, 116-119, 1990

330. Application of the B cell panel for immunological characterization of centrocytic and lymphocytic mucosa-associated B cell lymphomas
Huber H, Greil R, Stauder R, Lechleitner M, Fasching B, Thaler J, Glassl H, Radaskiewicz T, Gattringer C, Stein H
LEUCOCYTE TYPING IV, B 23.6, p 224-225, 1990

331. In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: Technical approach and comparison with results with anti-oncoprotein antibodies
Greil R, Fasching B, Huber H
LABORATORY INVESTIGATION, 60, 574-582, 1989

332. Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2 interferon and 2´deoxycoformycin
Thaler J, Denz H, Gastl G, Gattringer C, Greil R, Lechleitner M, Huber C, Huber H
LEUKEMIA RESEARCH, 13, 377-383, 1989

333. Expression of LFA-1 and 7F7 antigen, an adhesion molecule related to ICAM-1 influences growth pattern and spreading behaviour of Non-Hodgkin lymphomas and leukemias of B and T cell origin
Stauder R, Greil R, Schulz TF, Thaler J, Gattringer C, Radaskiewicz T, Dierich MP, Huber H
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 77, 234-238, 1989

334. Monoclonal antibody B-LY7: a new and sensitive marker for detection of minimal residual disease in hairy cell leukemias treated with interferon alpha-2 or 2´desoxycoformycin
Thaler J, Greil R, Dietze O, Huber H
LEUKEMIA, 4, 170-176, 1990

335. Expression des c-abl-Onkogens bei Non-Hodgkin Lymphomen: Untersuchungen mit Detektionssystemen auf Protein- und mRNA Ebene: Korrelation zu histologischer Differ-enzierung und klinische Relevanz
Greil R, Fasching B, Gattringer C, Cleveland J, Rapp U, Huber H
In LEUKÄMIEN UND LYMPHOME: FORTSCHRITTE UND HOFFNUNGEN. Herausgeber: Lutz D, Heinz R, Nowotny H, Stacher A, p 121, 1989.

336. abl oncogene expression in Non-Hodgkin lymphomas: correlation to histological differentiation and clinical status
Greil R, Gattringer C, Fasching B, Cleveland J, Thaler J, Radaskiewicz T, Gastl G, Huber C, Rapp U, Huber H
INTERNATIONAL JOURNAL OF CANCER, 42, 529-538, 1988

337. Importance of an 85 kd membrane glycoprotein for a variety of cell-cell interactions
Schulz TF, Vogetseder W, Mitterer M, Moynes BL, Stauder R, Greil R, Böck G, Faichtinger G, Huber H, Dierich MP
MOLECULAR IMMUNOLOGY, 25, 1053-1061, 1988

338. Teniposide (VM-26) and Cytosine Arabinoside as consolidation in adult high risk patients with acute lymphoblastic leukemia
Hoelzer D, Diehl V, Löffler H, Büchner T, Ganser A, Heil G, Kurrle S, Heimpel H, Koch P, Lipp T, Kaboth W, Kuse R, Küchler R Sodomann, Maschmeyer G, Freund M, Diedrich H, Paleske VA, Weh J, Kolb H, Müller U, Bross K, Fuhr G, Gassman W, Gerecke D, Kress M, Busch FW, Nowroussian RM, Schneider W, Aul C, Rühl H, Bartels H, Harms F, Weiss A, Löffler B, Glöckner W, Fülle H, Pralle H, Ho LAD, Bondert B, Emmerich B, Braumann D, Brennerserke M, Planker M, Straif K, Mer P, Greil R, Petsch S, Görg C, Grüneisen A, Vaurell HA, Bodenstein H, Overkamp F, Schlimock G, Augener Wühl S, Nowicki L, Raeth U, Zurborn KH, Neiss A, Messerer D
SEMINARS IN ONCOLOGY, 14, Supplementum,1, 92-97, 1987

339. Immunologische Markeruntersuchungen bei malignen Lymphomen: Diagnostische und prognostische Relevanz
Huber H, Thaler J, Greil R, Gattringer C, Radaskiewicz T
ONKOLOGIE, 9, 108-113, 1986

340. Growth fraction of tumour cells and infiltration density with human natural killer-like (HNK-1+) cells in Non-Hodgkin lymphomas
Greil R, Gattringer C, Knapp W, Huber H
BRITISH JOURNAL OF HAEMATOLOGY, 62, 293-300, 1986

341. Receptors for the third component of complement: Their association with maturation stage in Non-Hodgkin lymphomas and their possible implication in the development of follicular structures
Greil R, Gattringer C, Schulz T, Knapp W, Radaskiewicz T, Dierich MP, Huber H
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 64, 423-431, 1986

342. In situ quantification of T cell subsets, NK like cells and macrophages in Hodgkin's disease: Quantity and quality of infiltration density depends on histopathological subtypes
Gattringer C, Greil R, Radaskiewicz T, Huber H
BLUT, 45, 49-58, 1986. (nunmehr ANNALS OF HEMATOLOGY)

343. Rhabdomyolyse als Spätkomplikation einer Anästhesie: Ein Fall Maligner Hyperthermie?
Greil R, Gattringer C, Abbrederis K
WIENER KLINISCHE WOCHENSCHRIFT, 21, 813-816, 1985

344. Das Infiltrationsmuster immunkompetenter Lymphozyten im Gewebe maligner Non-Hodgkin Lymphome: Beziehungen zu histologischem Subtyp und klinischen Befunden
Gattringer C, Radaskiewicz T, Greil R, Pfaller W, Huber H
WIENER KLINISCHE WOCHENSCHRIFT, 5, 258-263, 1985

Die Klinik

Stationen, Ambulanzen & Einrichtungen

Suchen

Vorstand der 3. Universitätsklinik für Innere Medizin